1. Home
  2. PLG vs INO Comparison

PLG vs INO Comparison

Compare PLG & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Platinum Group Metals Ltd. (Canada)

PLG

Platinum Group Metals Ltd. (Canada)

N/A

Current Price

$0.86

Market Cap

140.7M

Sector

N/A

ML Signal

N/A

Logo Inovio Pharmaceuticals Inc.

INO

Inovio Pharmaceuticals Inc.

N/A

Current Price

$1.71

Market Cap

167.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLG
INO
Founded
2000
1979
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.7M
167.5M
IPO Year
2002
1999

Fundamental Metrics

Financial Performance
Metric
PLG
INO
Price
$0.86
$1.71
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $6.33
AVG Volume (30 Days)
1.1M
★ 18.9M
Earning Date
11-30-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.18
EPS
★ N/A
N/A
Revenue
N/A
★ $42,220,086.00
Revenue This Year
N/A
$434.61
Revenue Next Year
N/A
$23,912.63
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 19.37
52 Week Low
$0.90
$0.56
52 Week High
$4.04
$2.72

Technical Indicators

Market Signals
Indicator
PLG
INO
Relative Strength Index (RSI) 28.65 63.16
Support Level N/A $1.08
Resistance Level $1.44 $1.94
Average True Range (ATR) 0.07 0.23
MACD -0.01 0.04
Stochastic Oscillator 4.61 63.18

Price Performance

Historical Comparison
PLG
INO

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Share on Social Networks: